FDA Approved Astellas’ VEOZAH for Menopause Vasomotor Symptoms
On May 12, Astellas Pharma Inc announced that the FDA had approved VEOZAHTM (fezolinetant) 45 mg once daily for the
Read MoreOn May 12, Astellas Pharma Inc announced that the FDA had approved VEOZAHTM (fezolinetant) 45 mg once daily for the
Read More